Share Twitter LinkedIn Facebook Email Hagop Kantarjian, MD of MD Anderson Cancer Center discusses how FLT3 occurs in about a third of adult AML patients and may prove very important at the Scripps 36th Annual Conference: Clinical Hematology and Oncology in San Diego.
FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia Acute Lymphoblastic Leukemia 3 Mins Read
FDA Approves Inotuzumab Ozogamicin (BESPONSA) for Acute Lymphoblastic Leukemia in Pediatric Patients [Exclusive Video] Acute Lymphoblastic Leukemia 3 Mins Read
Spotlight on CAR T-cell Therapy in 2024: Advances & Clinical Insights Acute Lymphoblastic Leukemia 3 Mins Read